Comparison of the Chondrogenic Potential of EBMSCs and EUCMSCs in Response to Selected Peptides and Compounds

Overview

Journal BMC Vet Res

Publisher Biomed Central

Specialty Veterinary Medicine

Date 2025 Feb 16

PMID 39956895

Authors

Boushra Ajeeb

Emi A Kiyotake

Peggy A Keefe

Jennifer Nikki Phillips

Jennifer N Hatzel

Laurie R Goodrich

Michael S Detamore

Affiliations

Soon will be listed here.

Abstract

Background: Cartilage injuries pose significant challenges in horses and often lead to post-traumatic osteoarthritis (PTOA). Despite the advances in surgical and regenerative techniques, the result in most cases is the formation of a fibrocartilage repair tissue. Cell-based cartilage therapies are mainly focused on equine bone marrow-derived mesenchymal stem cells (eBMSCs) as they are easily accessible, and multipotent. Nonetheless, alternative allogeneic sources, for example equine umbilical cord matrix mesenchymal stromal cells (eUCMSCs), hold promise given their non-invasive and readily accessible nature. Considerable research has been dedicated to exploring chondroinductive factors (e.g., peptides and small compounds), aiming to replace growth factors for inducing chondrogenesis. However, these factors have not yet translated to the equine community. Therefore, in the current study, we selected from the literature two promising peptides, CM10 and CK2.1, and two promising compounds, kartogenin and SM04690, and assessed their chondroinductive potential with both eBMSCs and eUCMSCs. In addition, the chondroinductive potential of eBMSCs was evaluated in monolayer and spheroid culture in both hypoxia and normoxia in response to dexamethasone and/or transforming growth factor beta 3 (TGF-β3).

Results: Following 21 days of culture, none of the evaluated chondrogenic factors resulted in a higher gene expression of chondrogenic markers compared to the positive or negative controls with eBMSCs or eUCMSCs. Interestingly, spheroid culture in hypoxia with dexamethasone treatment (without TGF-β or any compound or peptide) was sufficient to induce the chondrogenic differentiation of eBMSCs.

Conclusion: Based on cell response to the positive control, in the conditions employed in the current study, eBMSCs may be preferred over eUCMSCs for chondrogenesis. The current study supports the use of spheroid culture, and the use of dexamethasone over TGF-β or any of the compounds or peptides tested here from the prior literature to drive chondrogenesis with eBMSCs.

References

Deshmukh V, Hu H, Barroga C, Bossard C, Kc S, Dellamary L . A small-molecule inhibitor of the Wnt pathway (SM04690) as a potential disease modifying agent for the treatment of osteoarthritis of the knee. Osteoarthritis Cartilage. 2017; 26(1):18-27. DOI: 10.1016/j.joca.2017.08.015. View

Mirza M, Bommala P, Richbourg H, Rademacher N, Kearney M, Lopez M . Gait Changes Vary among Horses with Naturally Occurring Osteoarthritis Following Intra-articular Administration of Autologous Platelet-Rich Plasma. Front Vet Sci. 2016; 3:29. PMC: 4829588. DOI: 10.3389/fvets.2016.00029. View

Bosch G, van Schie H, de Groot M, Cadby J, van de Lest C, Barneveld A . Effects of platelet-rich plasma on the quality of repair of mechanically induced core lesions in equine superficial digital flexor tendons: A placebo-controlled experimental study. J Orthop Res. 2009; 28(2):211-7. DOI: 10.1002/jor.20980. View

Nixon A, Begum L, Mohammed H, Huibregtse B, OCallaghan M, Matthews G . Autologous chondrocyte implantation drives early chondrogenesis and organized repair in extensive full- and partial-thickness cartilage defects in an equine model. J Orthop Res. 2011; 29(7):1121-30. DOI: 10.1002/jor.21366. View

McIlwraith C, Frisbie D . Microfracture: Basic Science Studies in the Horse. Cartilage. 2015; 1(2):87-95. PMC: 4297049. DOI: 10.1177/1947603510367427. View

Johnson K, Zhu S, Tremblay M, Payette J, Wang J, Bouchez L . A stem cell-based approach to cartilage repair. Science. 2012; 336(6082):717-21. DOI: 10.1126/science.1215157. View

Frisbie D, Kawcak C, Werpy N, Park R, McIlwraith C . Clinical, biochemical, and histologic effects of intra-articular administration of autologous conditioned serum in horses with experimentally induced osteoarthritis. Am J Vet Res. 2007; 68(3):290-6. DOI: 10.2460/ajvr.68.3.290. View

Akkiraju H, Srinivasan P, Xu X, Jia X, Safran C, Nohe A . CK2.1, a bone morphogenetic protein receptor type Ia mimetic peptide, repairs cartilage in mice with destabilized medial meniscus. Stem Cell Res Ther. 2017; 8(1):82. PMC: 5395786. DOI: 10.1186/s13287-017-0537-y. View

De Schauwer C, Piepers S, Van de Walle G, Demeyere K, Hoogewijs M, Govaere J . In search for cross-reactivity to immunophenotype equine mesenchymal stromal cells by multicolor flow cytometry. Cytometry A. 2012; 81(4):312-23. DOI: 10.1002/cyto.a.22026. View

10.

Deschaseaux F, Gindraux F, Saadi R, Obert L, Chalmers D, Herve P . Direct selection of human bone marrow mesenchymal stem cells using an anti-CD49a antibody reveals their CD45med,low phenotype. Br J Haematol. 2003; 122(3):506-17. DOI: 10.1046/j.1365-2141.2003.04469.x. View

11.

Wang L, Ott L, Seshareddy K, Weiss M, Detamore M . Musculoskeletal tissue engineering with human umbilical cord mesenchymal stromal cells. Regen Med. 2010; 6(1):95-109. PMC: 3057462. DOI: 10.2217/rme.10.98. View

12.

Akkiraju H, Bonor J, Nohe A . CK2.1, a novel peptide, induces articular cartilage formation in vivo. J Orthop Res. 2016; 35(4):876-885. PMC: 5522739. DOI: 10.1002/jor.23342. View

13.

Bodo G, Vasarhelyi G, Hangody L, Modis L . Mosaic arthroplasty of the medial femoral condyle in horses - An experimental study. Acta Vet Hung. 2013; 62(2):155-68. DOI: 10.1556/AVet.2013.059. View

14.

Sober S, Darmani H, Alhattab D, Awidi A . Flow cytometric characterization of cell surface markers to differentiate between fibroblasts and mesenchymal stem cells of different origin. Arch Med Sci. 2023; 19(5):1487-1496. PMC: 10507789. DOI: 10.5114/aoms/131088. View

15.

Garbin L, Morris M . A Comparative Review of Autologous Conditioned Serum and Autologous Protein Solution for Treatment of Osteoarthritis in Horses. Front Vet Sci. 2021; 8:602978. PMC: 7933025. DOI: 10.3389/fvets.2021.602978. View

16.

Wang L, Weiss M, Detamore M . Recent Patents Pertaining to Immune Modulation and Musculoskeletal Regeneration with Wharton's Jelly Cells. Recent Pat Regen Med. 2015; 3(3):182-192. PMC: 4533117. DOI: 10.2174/22102965113039990020. View

17.

Bragdon B, Thinakaran S, Moseychuk O, King D, Young K, Litchfield D . Casein kinase 2 beta-subunit is a regulator of bone morphogenetic protein 2 signaling. Biophys J. 2010; 99(3):897-904. PMC: 2913199. DOI: 10.1016/j.bpj.2010.04.070. View

18.

McIlwraith C, Frisbie D, Rodkey W, Kisiday J, Werpy N, Kawcak C . Evaluation of intra-articular mesenchymal stem cells to augment healing of microfractured chondral defects. Arthroscopy. 2011; 27(11):1552-61. DOI: 10.1016/j.arthro.2011.06.002. View

19.

Broeckx S, Martens A, Bertone A, Van Brantegem L, Duchateau L, Van Hecke L . The use of equine chondrogenic-induced mesenchymal stem cells as a treatment for osteoarthritis: A randomised, double-blinded, placebo-controlled proof-of-concept study. Equine Vet J. 2019; 51(6):787-794. PMC: 6850029. DOI: 10.1111/evj.13089. View

20.

Hamilton A, Townsend J, Detamore M . Automated Decellularization of Musculoskeletal Tissues with High Extracellular Matrix Retention. Tissue Eng Part C Methods. 2022; 28(4):137-147. DOI: 10.1089/ten.TEC.2022.0005. View